Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection.
A simple reversed phase high performance liquid chromatographic (HPLC) method was developed for the separation and quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA), and other retinoids in rat plasma. VN/14-1RA, alone or in combination with ATRA, is effective at inhibiting the proliferation of prostate and breast cancer cell lines in vitro. Aliquots of rat plasma were spiked with the retinoids followed by addition of acetonitrile for precipitation of plasma proteins. The decanted supernatant was evaporated under a stream of nitrogen and reconstituted in acetonitrile. Analysis was accomplished by injection of an aliquot of the reconstituted sample into an HPLC system consisting of a Zorbax Rx-C18 column and a diode array detector. A mobile phase composed of ammonium acetate (0.1 M), acetic acid solution (2% (v/v)) and methanol at a flow rate of 1.0 mL/min was used for gradient elution. The recoveries for all compounds ranged from 65 to 85% regardless of the concentrations examined. The HPLC assay was linear over the range 0.10-5.0 microg/mL (CV < 10%) with a limit of quantification of 100 ng/mL for VN/14-1RA. A one-compartment model with apparent first-order elimination was used to describe the plasma concentration-time profile for VN/14-1RA after intravenous administration. The mean terminal elimination half-life (t(1/2)) was 19.0 +/- 3.2 min. This HPLC method is useful for the analysis and evaluation of the pharmacokinetics of VN/14-1RA in rats.
Wu
Chunyu
C
Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA.
Njar
Vincent
V
Brodie
Angela
A
Borenstein
Michael
M
Nnane
Ivo
I
D000818:Animals; D000963:Antimetabolites / Q000097:blood* / Q000493:pharmacokinetics / Q000494:pharmacology; D002138:Calibration; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D004563:Electrochemistry; D007093:Imidazoles / Q000097:blood* / Q000493:pharmacokinetics / Q000494:pharmacology; D007202:Indicators and Reagents; D007275:Injections, Intravenous; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012015:Reference Standards; D015203:Reproducibility of Results; D012176:Retinoids / Q000097:blood* / Q000494:pharmacology; D013056:Spectrophotometry, Ultraviolet; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000097:blood* / Q000378:metabolism* / Q000493:pharmacokinetics / Q000494:pharmacology
C496751:4-(1H-imidazol-1-yl)retinoic acid; D000963:Antimetabolites; D007093:Imidazoles; D007202:Indicators and Reagents; D012176:Retinoids; D014212:Tretinoin